Diaphragm paralysis may cause symptomatic respiratory disturbances, and often occurs as a result of iatrogenic or traumatic phrenic nerve injury. Treatment options have been limited to plication of the diaphragm, however it is likely that most patients receive no therapeutic intervention regardless of the severity of symptoms. Although nerve transplantation is efficacious for various peripheral nerve injuries, it has only begun to be established for analogous conditions involving the phrenic nerve.

Thirty consecutive patients presenting with chronic, symptomatic phrenic nerve injuries following surgery, chiropractic manipulation, trauma or anesthetic blocks underwent a comprehensive evaluation, including radiographic and electrophysiologic assessments. Inclusion criteria consisted of patients who failed to improve...
Oral Presentation

Abstract printing supported by Chiesi. Visit Chiesi at Stand B2.10

Room Lehar 3-4 - 08:30 - 10:30

MONDAY, SEPTEMBER 3RD 2012

1685 Failure of Nissen fundoplication in chronic cough: Evidence for gaseous reflux
Daiana Stolz1, Warren Jackson2, Jennifer M. Burke3, Jaymin B. Morjaria1

Introduction: Acute diagnosis and management of airway reflux induced chronic cough is challenging. Nissen Fundoplication (NF) is a recognised treatment option for patients who fail medical treatment. Unfortunately some patients continue to be symptomatic even after NF.

Aim: To assess propharyngeal gaseous pH in patients who failed to respond to NF

Methods: Retrospective case review of 22 patients who remained symptomatic post NF at Castle Hill Hospital, UK. All subjects had pre-NF oesophageal manometry, 24 hours ambulatory pH monitoring and a post NF oesophageal pH measurement using Restech Dx-pH measurement system. One of these patients had follow up 24 hour ambulatory PH monitoring.

Results: Total of 22 patients (18 female) with a mean age of 45(range22-72) continued to report symptoms of chronic cough. All of these patients continued to have troublesome cough evidenced by a high Hull Cough Hypersensitivity Score with a mean score of 39(range 25-46), normal < 12. 15(68.2%) of these patients had an abnormal oesophageal pH study with a mean upper pH range of 4.5(range1.5-7.7), normal < 4.1. All of the 7 patients who had 24 hour oesophageal pH monitoring had a normal DeMeester score with a mean of 3.4(range1.5-6.4), normal < 7.2. Of the 15 patients with a normal DeMeester score 5 had an abnormal upper airway pH with a mean Ryan score of 175.2(range17.2-573.46).

Conclusion: The data suggest that NF eliminated significant acid reflux. A significant proportion of patients continued to have airway reflux as evidenced by a positive Ryan score. This implies that the aetiology of chronic cough lies in impaction of gaseous reflux in the pharynx and upper airways rather than the liquid reflux detected on conventional testing.

1686 Proadrenomedullin improves the prognostic property of the BODE index
Daiana Stolz1, Wim Boersma2, Bransilava Milenkovic1, Kostantinos Kostikas4, Francesco Blasi3, Joachim Aerts5, Renaud Louis6, Gernot Rohde8, Alina Lacoma1, Lucas Bocek1, Janku Raku7, Andreas Scher7, Anna4, Torgny Weiland5, Oliver Hartmann6, Michael Tamm1

1Pneumology, University of Medicine and Science, Bialystok, Poland
2Pneumology, University Hospital, Basel, Switzerland
3Pneumology, Medizin Centrum, Almhauz, Netherlands
4Pneumology, Institute for Pathology and Bacteriology, Scientific Center, Serbia
5University, Thesaloukiki Medical School, Thessaloniki, Greece
6Pneumology, IRCSS Policlinico, Milan, Italy
7Pneumology, Ampithia Hospital, Breda, Netherlands
8Pneumology, University of Liege, Belgium
9Pneumology, University Hospital, Maastricht, Netherlands
10Microbiology, University Hospital Germans Trias i Pujol, Badalona, Spain
11Pneumology, Hospital Clinic, Barcelona, Spain
12Pneumology, Medizinische Hochschule, Hannover, Germany
13Clinical Diagnosis, Thermo Scientific Biomarkers, Henningdorf, Germany

Background: The BODE index, a multidimensional grading system assessing the respiratory and systemic expressions of COPD, proved helpful in the prognostic assessment in COPD. We hypothesize that systemic biomarkers might additionally improve categorization and outcome prediction in COPD.

Methods: We prospectively evaluated 638 patients with stable COPD for ≥ 6 weeks, > 10 PD and GOLD II-IV seeking care in pulmonary tertiary hospitals in 8 European countries and included in the PROMISE cohort. The primary outcome of the study was death from any cause and from respiratory causes. Median observation time was 24 months.

Results: There were 63 deaths among the 638 patients (9.9%). 32 (51%) of the deaths were attributed mainly to COPD. Patients with higher proadrenomedullin values were at higher risk for death (p<0.0001). In the multivariate analysis proadrenomedullin HR (95% CI) 1.83 (1.34-2.51, p=0.0002), BMI 0.48 (0.32-0.72, p=0.0004) and 6 MWD 0.6 (0.4-0.91, p=0.0152) but not MMRC 1.31 (0.98-1.74, p=0.0115) and FEV1/forced vital capacity (1.7 0.48-1.7, p=0.5277) were significantly associated with 2 year survival. The C-index for the prediction of mortality in the Cox-regression analysis was 0.676 for the BODE index and 0.658 for proadrenomedullin (p<0.0001 both). The addition of proadrenomedullin to the BODE index improved its performance significantly (C-index 0.743, p=0.00020). In combination with proadrenomedullin, the BMI (B), the degree of airflow obstruction (O) and dyspnea (D) domains by itself (e.g. without exercise capacity) performed similarly to the BODE index (C-index 0.772).

Conclusion: Proadrenomedullin improves the performance of the BODE index at predicting the risk of death from any cause among patients with COPD.

1687 Is the bacterium Tropheryma whipplei cause of the disease in a subgroup of patients with presumed sarcoidosis?
Dejene Shiferaw1,2, Marion Houlberg1,2, Christian Müller2, Wolfgang Piekierski2, Melissa Dadic2, Sabine Publig2, Reinhard Kneuss2, Michael Gschwantler1,2,3
1Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria
2Department of Internal Medicine III, AKH & Medical University Vienna, Vienna, Austria
3Institute of Pathology and Bacteriology, Wilhelminenspital, Vienna, Austria

Introduction: Recently we published a case report presenting a patient in whom a causal relationship between pulmonary sarcoidosis and infection with Tropheryma whipplei (T. whipplei) could be demonstrated. To our best knowledge this is the first systematic study investigating the hypothesis, that in a subgroup of patients presumed sarcoidosis is caused by T. whipplei.

Patients and methods: A total of 56 consecutive patients in whom a diagnosis of sarcoidosis was suspected clinically and confirmed histologically were included in this retrospective study (mf = 21:35, mean age:±SD = 53.6±16.2 (range 24–90 years).

PCR-examination for T. whipplei was performed in all patients, using formalin-fixed and paraffin-embedded specimens obtained from organs affected by sarcoidosis (lung (n=22), lymph nodes (n=15), skin (n=7), liver (n=6), other organs (n=4)). All PCR-examinations were done in an international reference laboratory for Whipple’s disease.

Results: T. whipplei-RNA was detected in tissues affected by sarcoidosis in 2 of 56 patients (3.6%). Both patients were women (age: 32 and 85 years, respectively) and had enlarged mediastinal and hilar lymph nodes. Histological examination of affected lymph nodes showed granulomatous lymphadenitis of sarcoid type, PAS-staining was negative. Both patients had no gastrointestinal symptoms. Further examination for the presence of Whipple’s disease was ongoing.

Conclusion: Our findings contribute further evidence to the hypothesis, that in a subgroup of patients presumed sarcoidosis is caused by infection with the bacterium T. whipplei. However, this hypothesis should be further evaluated in prospective studies.

1Lancet 2007; 369:1832.

1688 Sarcoidosis relapses in corticosteroid treated patients
Leonora Lomia1, Cornelia Tudose2, Dragos Bumbaca2, Bersandia Clit2, Ioan Paul Stoneescu2,1
1Respiratory Physiopathology, M. Nasta Institute of Pneumology, Bucharest, Romania
2Clinical Pneumology, M. Nasta Institute of Pneumology, Bucharest, Romania

Aim: Assessing the frequency of relapses and the disease characteristics associated with relapses in corticosteroid treated sarcoidosis patients.

Subjects and methods: 125 patients with biopsy-proven sarcoidosis treated with corticosteroids for 6-18 months after diagnosis were evaluated. Number and type of relapses were noted during the follow-up period. The clinical and laboratory parameters were compared in patients with a relapse of the disease versus (vs) patients without relapses.

Results: 38 patients (30%) had a sarcoidosis relapse, 2-42 months after the treatment stop (mean interval 11.38±7.4 years). The patients with relapses had more frequent interstitial lung disease at diagnosis versus (vs) patients without relapses.

Conclusion: Almost one third of the sarcoidosis patients in which corticosteroid treatment was necessary at diagnosis had a disease relapse during the follow-up period. Disease severity at diagnosis or at the end of the first corticosteroid treatment and the short duration of the treatment were associated with the occurrence of a relapse.
1689
Occurrence of hypersensitivity to beryllium among patients with diagnosed sarcoidosis. Initial results
Lukasz Kasper1, Krysztof Sladek1, Jerzy Soja1, Hanna Plutecka2, Marek Sanak1, 2
1Division of Thoracoscopy and Bronchoscopy, Jagiellonian University, Cracow, Poland; 2Division of Molecular Biology and Clinical Genetics, Jagiellonian University, Cracow, Poland

Introduction: Sarcoidosis is a form of interstitial lung disease of unknown cause. In this disease the formations of granulomas are diagnosed also among individuals with berylliosis – an occupational disease clinically similar to sarcoidosis, but associated with hypersensitivity to beryllium.

Aim of study: Our objective is to determine the frequency of hypersensitivity to beryllium in individuals with diagnosed sarcoidosis and to attempt to work out diagnostic methods of berylliosis.

Methodology: Individuals selected for the research were diagnosed with sarcoidosis. All individuals were screened using a modified beryllium lymphocyte proliferation test (BeLPT). The method involved isolating blood lymphocytes, staining them with fluorescent marker (CFSE) and exposing them to beryllium sulfate (of various concentration) or mitogen (positive control). The number of dividing cells (CFSE dilution) was marked after 5 days of incubation with flow cytometry. Individuals suspected of positive proliferation test result and those suspected of the risk for beryllium compounds exposure will be examined by patch tests with beryllium sulfate.

Results: 30 individuals with sarcoidosis have been tested. 5 of them (14.3%) exhibited increased lymphocyte proliferation index.

Conclusions: The study attempts to present a new diagnostic method of identifying hypersensitivity to beryllium. Presently, neither reliable in vitro tests for berylliosis have been standardised nor routinely carried out. Our method requires validation among patients with berylliosis, testing the method in control group and comparison of BeLPT-CFSE methods with a standard thymidine test.

1690
Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion
Sayas Ozgu1, Yasim Abul1, Ahmet Mentese2, Hayriye Bektas2, Aysegul Uzun2, Tevzik Ozlu1, 2Department of Chest, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey; 1Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Pentraxin-3 (PTX-3) is a new marker of inflammation. Pentraxins like C-reactive protein are key components of the innate immune system. Diagnostic value of PTX-3 in parapneumonic pleural effusion (PPPE) and malignant pleural effusion (MPE) has not been examined before. The concentrations of pleural fluid PTX-3 were measured in a total of 61 patients: 20 with PPPE and 41 with MPE. A diagnosis PPPE was based upon the presence of an effusion in patients with clinical and radiological evidence of acute pneumonia. A malignant pleural effusion (PE) was defined by pleural biopsy or the presence of malignant cells on PE cytology. The area under the curve (AUC) quantified the overall diagnostic accuracy of the tests. The study demonstrated that PTX-3 concentration was higher in pleural fluid of PPPE patients compared with MPE patients (31.8 ng/mL vs 6.9 ng/mL respectively; p<0.001). Pleural effusion PTX-3 demonstrated AUCs of 0.802 (95% CI 0.683-0.921, P<0.001) for diagnosing effusions due to PPPE. The sensitivity and specificity of PE-PTX-3 for PPPE at the cut-off concentration of 8.5 ng/mL was 80% and 64%, respectively. Measuring PTX-3 concentrations in pleural fluid may be helpful in distinguishing pleural effusion due to a PPPE or MPE aetiology.

1691
Diagnostic accuracy of pleural fluid NTpro-BNP for pleural effusions of cardiac origin
Juan Antonio Mazzig1, Juan Bourbote1, Marcelo Melero1, Daniel Piñeiro1, Griselda Pargament2, Marcela Catro3, 1Medicine Department, Hospital de Clínicas Jose de San Martin - Universidad de Buenos Aires, Argentina; 2Biochemistry Department, Hospital de Clínicas Jose de San Martin - Universidad de Buenos Aires, Argentina

Introduction: The most frequent cause of a pleural effusion is heart failure. The diagnosis is based on clinical findings and biochemical parameters.

Rationale: The existence of a specific heart biomarker could avoid unnecessary studies for the diagnosis of cardiac origin of pleural fluids.

Objective: The purpose of our study was to evaluate the diagnostic accuracy of pleural fluid aminoterminal fragment N-terminal pro-brain natriuretic peptide (NTpro-BNP) for pleural effusions of cardiac origin compared with Framingham criteria.

Material and methods: We studied 32 consecutive patients admitted at the work site. Pleural and blood samples were simultaneously obtained NTpro-BNP was measured in blood and pleural fluids (Bio Merieux® Enzyme-Linked Fluorescent Assay). Light criteria and serum-pleural albumin gradient was used to discriminate transudates from exudates.

Results: The cut-off value of pleural fluid NTpro-BNP level to discriminate between pleural effusions due to heart failure was 1.791 pg/mL. The sensitivity and specificity was 75.0%(95%CI 47.6-92.6) and 81.2%(95%CI 54.4-95.7) respectively; with a positive predictive value of 80.0%(95%CI 51.9-96.0), negative predictive value 81.8%(95%CI 50.1-93.2), positive likelihood ratio 4.6(95%CI 20.8-5.8) and negative likelihood ratio 0.3(95%CI 0.1-1.2).

Conclusions: Pleural fluid NTpro-BNP is a very useful biomarker with high diagnostic accuracy for distinguishing pleural effusions of cardiac origin.